Mesoblast Ltd
ASX:MSB
Mesoblast Ltd
ASX:MSB
Price:
1.175 AUD
-0.42%
Market Closed
Updated:
May 27, 2024
Mesoblast Ltd
Income from Continuing Operations
|
Mesoblast Ltd
Income from Continuing Operations Peer Comparison
Comparables:
IMM
CSL
CUV
TLX
PYC
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Mesoblast Ltd
ASX:MSB
|
Income from Continuing Operations
-$73.1m
|
CAGR 3-Years
9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Immutep Ltd
ASX:IMM
|
Income from Continuing Operations
-AU$40.5m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-12%
|
|
|
CSL Ltd
ASX:CSL
|
Income from Continuing Operations
$2.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Income from Continuing Operations
AU$30.2m
|
CAGR 3-Years
13%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Income from Continuing Operations
AU$5.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Income from Continuing Operations
-AU$21.7m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-23%
|
See Also
What is Mesoblast Ltd's Income from Continuing Operations?
Income from Continuing Operations
-73.1m
USD
-73.1m
USD
Based on the financial report for Dec 31, 2023, Mesoblast Ltd's Income from Continuing Operations amounts to -73.1m USD.
What is Mesoblast Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
3%
3%
Over the last year, the Income from Continuing Operations growth was 28%. The average annual Income from Continuing Operations growth rates for Mesoblast Ltd have been 9% over the past three years , 3% over the past five years .
You don't have any saved screeners yet
